Global and China Glucagon Like Peptide-1 (GLP-1) Agonists Market Insights, Forecast to 2027

Publisher Name :
Date: 10-Sep-2021
No. of pages: 137
Inquire Before Buying

Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.

Market Analysis and Insights: Global and China Glucagon Like Peptide-1 (GLP-1) Agonists Market

This report focuses on global and China Glucagon Like Peptide-1 (GLP-1) Agonists market.

In 2020, the global Glucagon Like Peptide-1 (GLP-1) Agonists market size was US$ 7781.9 million and it is expected to reach US$ 18650 million by the end of 2027, with a CAGR of 13.3% during 2021-2027. In China the Glucagon Like Peptide-1 (GLP-1) Agonists market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Glucagon Like Peptide-1 (GLP-1) Agonists Scope and Market Size

Glucagon Like Peptide-1 (GLP-1) Agonists market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Glucagon Like Peptide-1 (GLP-1) Agonists market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.

For China market, this report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.

Segment by Type

- Exenatied

- Liraglutide

- Lixisenatide

- Albiglutide

- Dulaglutide

Segment by Application

- Hospital

- Pharmacy

- Other

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - India

- - Australia

- - Taiwan

- - Indonesia

- - Thailand

- - Malaysia

- - Philippines

- - Vietnam

- Latin America

- - Mexico

- - Brazil

- - Argentina

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - U.A.E

By Company

- Novo Nordisk

- AstraZeneca

- Eli Lily

- GSK

- Sanofi

- Bristol-Myers Squibb

- Amylin

Global and China Glucagon Like Peptide-1 (GLP-1) Agonists Market Insights, Forecast to 2027

Table of Contents
1 Study Coverage
1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Product Introduction
1.2 Market by Type
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Market by Application
1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, Estimates and Forecasts
2.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue 2016-2027
2.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2027
2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Historical Market Size by Region (2016-2021)
2.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2022-2027)
2.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2022-2027)
3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Competitor Landscape by Players
3.1 Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers by Sales
3.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturer (2016-2021)
3.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers by Revenue
3.2.1 Key Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Covered: Ranking by Revenue
3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2016-2021)
3.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2020
3.2.6 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Manufacturers
3.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Base Distribution, Product Types
3.4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type
3.4.3 Date of International Manufacturers Enter into Glucagon Like Peptide-1 (GLP-1) Agonists Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Type (2016-2021)
4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2016-2021)
4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2016-2021)
4.1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Type (2022-2027)
4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2022-2027)
4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2022-2027)
4.2.3 Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Application (2016-2021)
5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2016-2021)
5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2016-2021)
5.1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2016-2021)
5.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Forecast by Application (2022-2027)
5.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2022-2027)
5.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2022-2027)
5.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Application (2022-2027)
6 China by Players, Type and Application
6.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
6.1.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales YoY Growth 2016-2027
6.1.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue YoY Growth 2016-2027
6.1.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Share in Global Market 2016-2027
6.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Players (International and Local Players)
6.2.1 China Top Glucagon Like Peptide-1 (GLP-1) Agonists Players by Sales (2016-2021)
6.2.2 China Top Glucagon Like Peptide-1 (GLP-1) Agonists Players by Revenue (2016-2021)
6.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Review by Type (2016-2021)
6.3.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
6.3.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2016-2021)
6.3.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2016-2021)
6.4 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2022-2027)
6.4.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2022-2027)
6.4.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Type (2022-2027)
6.5 China Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Review by Application (2016-2021)
6.5.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
6.5.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2016-2021)
6.5.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2016-2021)
6.6 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2022-2027)
6.6.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2022-2027)
6.6.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Application (2022-2027)
7 North America
7.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
7.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
7.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
7.2.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
8.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Region
8.2.1 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2016-2021)
8.2.2 Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam
9 Europe
9.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
9.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
9.2.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
9.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
10.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
10.2.1 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
10.2.2 Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Facts & Figures by Country
11.2.1 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021)
11.2.2 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Novo Nordisk
12.1.1 Novo Nordisk Corporation Information
12.1.2 Novo Nordisk Description and Business Overview
12.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.1.5 Novo Nordisk Recent Development
12.2 AstraZeneca
12.2.1 AstraZeneca Corporation Information
12.2.2 AstraZeneca Description and Business Overview
12.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.2.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.2.5 AstraZeneca Recent Development
12.3 Eli Lily
12.3.1 Eli Lily Corporation Information
12.3.2 Eli Lily Description and Business Overview
12.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.3.5 Eli Lily Recent Development
12.4 GSK
12.4.1 GSK Corporation Information
12.4.2 GSK Description and Business Overview
12.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.4.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.4.5 GSK Recent Development
12.5 Sanofi
12.5.1 Sanofi Corporation Information
12.5.2 Sanofi Description and Business Overview
12.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.5.5 Sanofi Recent Development
12.6 Bristol-Myers Squibb
12.6.1 Bristol-Myers Squibb Corporation Information
12.6.2 Bristol-Myers Squibb Description and Business Overview
12.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.6.5 Bristol-Myers Squibb Recent Development
12.7 Amylin
12.7.1 Amylin Corporation Information
12.7.2 Amylin Description and Business Overview
12.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.7.5 Amylin Recent Development
12.11 Novo Nordisk
12.11.1 Novo Nordisk Corporation Information
12.11.2 Novo Nordisk Description and Business Overview
12.11.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
12.11.5 Novo Nordisk Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
13.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
13.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
13.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Exenatied
Table 3. Major Manufacturers of Liraglutide
Table 4. Major Manufacturers of Lixisenatide
Table 5. Major Manufacturers of Albiglutide
Table 6. Major Manufacturers of Dulaglutide
Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Growth Rate by Application (2021-2027) & (K Units)
Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Regions (2016-2021) & (K Units)
Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Regions (2016-2021)
Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Regions (2016-2021) & (US$ Million)
Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Region (2022-2027) & (K Units)
Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Region (2022-2027)
Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Region (2022-2027)
Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturers (2016-2021) (K Units)
Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturers (2016-2021)
Table 18. Ranking of Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers by Revenue (US$ Million) in 2020
Table 19. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturers (2016-2021) (US$ Million)
Table 20. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Manufacturers (2016-2021)
Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2020)
Table 23. Key Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Price (2016-2021) (USD/Unit)
Table 24. Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Glucagon Like Peptide-1 (GLP-1) Agonists Product Type
Table 26. Date of International Manufacturers Enter into Glucagon Like Peptide-1 (GLP-1) Agonists Market
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2016-2021) (K Units)
Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2016-2021)
Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2016-2021) (US$ Million)
Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2016-2021)
Table 32. Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Table 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2022-2027) & (K Units)
Table 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Type (2022-2027)
Table 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast V (2022-2027) & (US$ Million)
Table 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Type (2022-2027)
Table 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Unit)
Table 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2016-2021) (K Units)
Table 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2016-2021)
Table 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2016-2021) (US$ Million)
Table 41. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2016-2021)
Table 42. Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Table 43. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2022-2027) & (K Units)
Table 44. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Application (2022-2027)
Table 45. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 46. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share Forecast by Application (2022-2027)
Table 47. Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Unit)
Table 48. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) of Key Companies (2016-2021)
Table 49. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Company (2016-2021)
Table 50. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) by Company (2016-2021)
Table 51. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Company (2016-2021)
Table 52. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Type (2016-2021)
Table 53. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2016-2021)
Table 54. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Market Share by Type (2016-2021)
Table 55. China Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Type (2016-2021)
Table 56. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Type (2022-2027)
Table 57. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2022-2027)
Table 58. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Market Share by Type (2022-2027)
Table 59. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2022-2027)
Table 60. China Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Type (2022-2027)
Table 61. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Application (2016-2021)
Table 62. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2016-2021)
Table 63. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Market Share by Application (2016-2021)
Table 64. China Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Application (2016-2021)
Table 65. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Application (2022-2027)
Table 66. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2022-2027)
Table 67. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Market Share by Application (2022-2027)
Table 68. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2022-2027)
Table 69. China Glucagon Like Peptide-1 (GLP-1) Agonists Price (USD/Unit) by Application (2022-2027)
Table 70. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 71. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 72. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 73. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 74. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Region (2016-2021) & (K Units)
Table 75. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2016-2021)
Table 76. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Region (2016-2021) & (US$ Million)
Table 77. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2016-2021)
Table 78. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 79. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 80. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 81. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 82. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 83. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 84. Latin Americaa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 85. Latin America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 86. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Country (2016-2021) & (K Units)
Table 87. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country (2016-2021)
Table 88. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Country (2016-2021) & (US$ Million)
Table 89. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country (2016-2021)
Table 90. Novo Nordisk Corporation Information
Table 91. Novo Nordisk Description and Business Overview
Table 92. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 93. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 94. Novo Nordisk Recent Development
Table 95. AstraZeneca Corporation Information
Table 96. AstraZeneca Description and Business Overview
Table 97. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 98. AstraZeneca Product
Table 99. AstraZeneca Recent Development
Table 100. Eli Lily Corporation Information
Table 101. Eli Lily Description and Business Overview
Table 102. Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 103. Eli Lily Product
Table 104. Eli Lily Recent Development
Table 105. GSK Corporation Information
Table 106. GSK Description and Business Overview
Table 107. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 108. GSK Product
Table 109. GSK Recent Development
Table 110. Sanofi Corporation Information
Table 111. Sanofi Description and Business Overview
Table 112. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 113. Sanofi Product
Table 114. Sanofi Recent Development
Table 115. Bristol-Myers Squibb Corporation Information
Table 116. Bristol-Myers Squibb Description and Business Overview
Table 117. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 118. Bristol-Myers Squibb Product
Table 119. Bristol-Myers Squibb Recent Development
Table 120. Amylin Corporation Information
Table 121. Amylin Description and Business Overview
Table 122. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 123. Amylin Product
Table 124. Amylin Recent Development
Table 125. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends
Table 126. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
Table 127. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
Table 128. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
Table 129. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List
Table 130. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture
Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2020 & 2027
Figure 3. Exenatied Product Picture
Figure 4. Liraglutide Product Picture
Figure 5. Lixisenatide Product Picture
Figure 6. Albiglutide Product Picture
Figure 7. Dulaglutide Product Picture
Figure 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2020 & 2027
Figure 9. Hospital
Figure 10. Pharmacy
Figure 11. Other
Figure 12. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered
Figure 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size 2016-2027 (US$ Million)
Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales 2016-2027 (K Units)
Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size Market Share by Region: 2021 Versus 2027
Figure 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2016-2021)
Figure 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region in 2020
Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2016-2021)
Figure 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region in 2020
Figure 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Manufacturer in 2020
Figure 22. The Top 10 and 5 Players Market Share by Glucagon Like Peptide-1 (GLP-1) Agonists Revenue in 2020
Figure 23. Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2016-2021)
Figure 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2020
Figure 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type (2016-2021)
Figure 27. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Type in 2020
Figure 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2016-2021)
Figure 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2020
Figure 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2016-2021)
Figure 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application in 2020
Figure 32. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2027 (K Units)
Figure 33. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2027 (US$ Million)
Figure 34. China Glucagon Like Peptide-1 (GLP-1) Agonists Market Share in Global Market 2016-2027
Figure 35. China 5 and 10 Largest Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists in 2020
Figure 36. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2016-2021)
Figure 37. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate by Type in 2016 & 2020
Figure 38. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2016-2021)
Figure 39. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate by Application in 2016 & 2020
Figure 40. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2021 (K Units)
Figure 41. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2021 (US$ Million)
Figure 42. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country in 2020
Figure 43. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country in 2020
Figure 44. U.S. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 45. U.S. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 47. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2021 (K Units)
Figure 49. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2021 (US$ Million)
Figure 50. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Country in 2020
Figure 51. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Country in 2020
Figure 52. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 53. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 54. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 55. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 56. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 57. U.K. Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 58. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 59. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 60. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2016-2021) (K Units)
Figure 61. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate (2016-2021) (US$ Million)
Figure 62. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate 2016-2021 (K Units)
Figure 63. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate 2016-2021 (US$ Million)
Figure 64. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region in 2020
Figure 65. Asia Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Marke
  • Global and United States Human Insulin Market Report & Forecast 2022-2028
    Published: 19-May-2022        Price: US 4350 Onwards        Pages: 105
    Human Insulin market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Human Insulin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028. For United States market, this report focuses on the Human Insulin market size by players, by Type and by Ap......
  • Genome-Based Drug Companies in China
    Published: 17-May-2022        Price: US 1800 Onwards        Pages: 86
    This study focuses on China's Genome-Based Drug industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions o......
  • Genome-Based Drug Industry Forecasts - China Focus
    Published: 17-May-2022        Price: US 1800 Onwards        Pages: 95
    This study focuses on China's Genome-Based Drug industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. T......
  • 2022-2030 Report on Global Glucagon Market by Player, Region, Type, Application and Sales Channel
    Published: 17-May-2022        Price: US 2500 Onwards        Pages: 109
    This report studies the Glucagon market, covering market size for segment by type (Inject Glucagon, Nasal Glucagon, etc.), by application (Emergency Kits, General Use, etc.), by sales channel (Direct Channel, Distribution Channel), by player (Novo Nordisk, Eli Lilly, Fresenius Kabi, Torrent Labs, Taj Pharmaceuticals, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market ......
  • Genome-Based Drug Markets in China
    Published: 17-May-2022        Price: US 4000 Onwards        Pages: 240
    China's demand for Genome-Based Drug has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, indus......
  • (Post-pandemic Era) - Global Antidiabetic Thiazolidinediones Market Segment Research Report 2022
    Published: 13-May-2022        Price: US 2950 Onwards        Pages: 102
    Summary The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery. 2022 is a year of continuous recovery. Global supply chain disturba......
  • (Post-pandemic Era) - Global Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Segment Research Report 2022
    Published: 13-May-2022        Price: US 2950 Onwards        Pages: 103
    Summary The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery. 2022 is a year of continuous recovery. Global supply chain disturba......
  • 2022-2029 Global Liraglutide Professional Market Research Report, Analysis from Perspective of Segmentation (Competitor Landscape, Type, Application, and Geography)
    Published: 10-May-2022        Price: US 2980 Onwards        Pages: 116
    The Liraglutide market has witnessed growth from USD XX million to USD XX million from 2017 to 2022. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2029. The report focuses on the Liraglutide market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides detailed cost analysis, supply chain. Technological innovation and adv......
  • 2022-2029 Global Antidiabetic Sglt-2 Inhibitor Professional Market Research Report, Analysis from Perspective of Segmentation (Competitor Landscape, Type, Application, and Geography)
    Published: 10-May-2022        Price: US 2980 Onwards        Pages: 122
    The Antidiabetic Sglt-2 Inhibitor market has witnessed growth from USD XX million to USD XX million from 2017 to 2022. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2029. The report focuses on the Antidiabetic Sglt-2 Inhibitor market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides detailed cost analysis, supply chain. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs